MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.32 1.54

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.29

Максимум

1.37

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+122.22% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-24M 79M
Предишно отваряне	-0.22
Предишно затваряне	1.32

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.01.2026 г., 22:18 ч. UTC

Пазарно говорене

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.01.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9.01.2026 г., 20:39 ч. UTC

Пазарно говорене

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9.01.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9.01.2026 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9.01.2026 г., 20:30 ч. UTC

Пазарно говорене

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9.01.2026 г., 20:15 ч. UTC

Пазарно говорене

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9.01.2026 г., 20:07 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.01.2026 г., 20:07 ч. UTC

Пазарно говорене

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9.01.2026 г., 19:58 ч. UTC

Придобивния, сливания и поглъщания

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9.01.2026 г., 19:42 ч. UTC

Пазарно говорене

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9.01.2026 г., 19:38 ч. UTC

Придобивния, сливания и поглъщания

Wolters Kluwer Acquires StandardFusion >WTKWY

9.01.2026 г., 19:31 ч. UTC

Печалби

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9.01.2026 г., 19:28 ч. UTC

Печалби

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9.01.2026 г., 18:30 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9.01.2026 г., 18:23 ч. UTC

Пазарно говорене

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

9.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.01.2026 г., 17:19 ч. UTC

Пазарно говорене

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9.01.2026 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.01.2026 г., 17:07 ч. UTC

Пазарно говорене

McDonald's Promotions Appear Successful -- Market Talk

9.01.2026 г., 17:06 ч. UTC

Пазарно говорене

Oil Futures on Track for Weekly Gains -- Market Talk

9.01.2026 г., 17:05 ч. UTC

Печалби

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9.01.2026 г., 16:57 ч. UTC

Пазарно говорене

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9.01.2026 г., 16:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.01.2026 г., 16:46 ч. UTC

Пазарно говорене

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

122.22% нагоре

12-месечна прогноза

Среден 3 USD 122.22%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.